Loading
Florastamin is FutureChem's fluorine-18 PSMA PET tracer from South Korea, in phase 3 trials for staging high-risk and recurrent prostate cancer alongside the established PSMA agents.
FutureChem, a Seoul radiopharmaceutical company, developed florastamin (FC303) as a fluorine-18 PSMA ligand for PET imaging of prostate cancer. Registered phase 3 trials assess it for initial staging of high-risk prostate cancer and for biochemical recurrence, the settings in which gallium-68 PSMA-11 and piflufolastat are already approved in the United States and Europe.
A fluorine-18-labelled ligand of prostate-specific membrane antigen that lights up prostate cancer on PET wherever it has spread. Connects to PSMA.
1.Florastamin F-18 slips into a pocket on PSMA.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Florastamin F-18" OR ABSTRACT:"Florastamin F-18" OR TITLE:"FC303" OR ABSTRACT:"FC303") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Florastamin F-18, not a curated reading list.
Shares PET (positron emission tomography), PSMA, PSMA PET, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PSMA, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.